Download Files:
Apratastat
$99 – $330
Products Details
Product Description
– Apratastat (TMI-005) is an orally active, non-selective and reversible TACE/MMPs inhibitor, can inhibit inhibit the release of TNF-α. Apratastat has the potential to overcome radiotherapy-resistance in non-small cell lung cancer (NSCLC)[1][2]. Apratastat is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Web ID
– HY-119307
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C17H22N2O6S2
References
– [1]Shu C, et al. Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach. J Clin Pharmacol. 2011 Apr;51(4):472-81.|[2]Ieguchi K, et al. Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer. J Thorac Dis. 2016 Aug;8(8):E813-5.
CAS Number
– 287405-51-0
Molecular Weight
– 414.50
Compound Purity
– 99.67
SMILES
– CC1(C)[C@H](C(NO)=O)N(S(=O)(C2=CC=C(OCC#CCO)C=C2)=O)CCS1
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 41.4 mg/mL (ultrasonic;warming)
Target
– MMP;TNF Receptor
Isoform
– CD40
Pathway
– Apoptosis;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
